Optiflow™ Nasal High Flow Therapy

HFNC, HFOT, NHF... While many acronyms have been used for this therapy, one name stands out as the way to deliver it: Optiflow

Optiflow Nasal High Flow from Fisher & Paykel Healthcare is at the forefront of the field, featuring in hundreds of publications and appearing in such prestigious journals as the NEJM and JAMA.

Improving Care and Outcomes

The Optiflow mechanisms of action are:

• Respiratory support (through Reduction of dead space and delivery of a Dynamic positive airway pressure)
• Airway hydration
• Patient comfort
• Supplemental oxygen (if required)

These mechanisms contribute to physiological effects such as reduced respiratory rate, improved oxygenation, reduced carbon dioxide levels and improved mucus clearance.

Clinical studies suggest that Optiflow may reduce escalation of care, reduce mortality rates and improve symptomatic relief.

Use Optiflow to reduce escalation

A patient's journey through hospital may include periods of escalation and de-escalation of care. Consider this conceptual model, at left, showing two patients' journeys through hospital. The costs for these journeys are denoted by the areas of blue and red.

Using Optiflow as a first-line treatment (both pre-intubation and post-extubation) may reduce a patient's escalation "up the acuity curve", resulting in better patient outcomes and reduced costs of care.

We call this Optiflow FIRST.

Nasal High Flow and COPD focused webinar

Learn more about Nasal High Flow and myAIRVO.

Associate Professor Ulla Møller Weinreich speaks about her research "Humidified High Flow therapy for chronic COPD patients" in this Nasal High Flow and COPD focused webinar.